Sei Investments Co. Purchases 28,453 Shares of Alkermes PLC (ALKS)
Sei Investments Co. boosted its position in shares of Alkermes PLC (NASDAQ:ALKS) by 31.5% during the second quarter, Holdings Channel reports. The institutional investor owned 118,778 shares of the company’s stock after buying an additional 28,453 shares during the period. Sei Investments Co.’s holdings in Alkermes PLC were worth $6,886,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Daiwa SB Investments Ltd. purchased a new position in Alkermes PLC during the second quarter worth $166,000. Greenwood Capital Associates LLC increased its position in Alkermes PLC by 2.4% in the first quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock worth $218,000 after buying an additional 89 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after buying an additional 224 shares in the last quarter. US Bancorp DE increased its position in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after buying an additional 3,122 shares in the last quarter. Finally, Insight Capital Research & Management Inc. purchased a new position in Alkermes PLC during the second quarter worth $232,000. 97.19% of the stock is currently owned by institutional investors.
Shares of Alkermes PLC (NASDAQ:ALKS) opened at 51.62 on Tuesday. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40. The company’s 50 day moving average price is $56.54 and its 200 day moving average price is $57.26. The stock’s market cap is $7.93 billion.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. The business had revenue of $218.80 million during the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.01) EPS. On average, analysts anticipate that Alkermes PLC will post ($0.04) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Sei Investments Co. Purchases 28,453 Shares of Alkermes PLC (ALKS)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/sei-investments-co-purchases-28453-shares-of-alkermes-plc-alks/1488931.html.
Several research analysts have recently commented on ALKS shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $62.00 price objective on shares of Alkermes PLC in a research note on Monday, April 24th. J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the stock a “buy” rating in a research note on Thursday, April 27th. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research note on Friday, April 28th. Credit Suisse Group set a $70.00 price objective on Alkermes PLC and gave the stock a “buy” rating in a research note on Friday, May 19th. Finally, ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Alkermes PLC currently has a consensus rating of “Hold” and an average target price of $63.00.
In other news, Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the transaction, the director now owns 680,406 shares of the company’s stock, valued at approximately $39,592,825.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael J. Landine sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $57.23, for a total value of $572,300.00. Following the completion of the transaction, the senior vice president now directly owns 167,370 shares of the company’s stock, valued at approximately $9,578,585.10. The disclosure for this sale can be found here. In the last three months, insiders sold 99,500 shares of company stock valued at $5,776,365. Insiders own 5.34% of the company’s stock.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.